La résistance à un antimicrobien survient quand un micro-organisme (bactérie, virus, champignon ou parasite), devient résistant à un médicament antimicrobien vis-à-vis duquel il était auparavant sensible . Cette résistance... aux antimicrobiens (RAM), concerne un large éventail d’agents infectieux, et de nombreux secteurs d’activités (santé humaine et animale, agro-industrie, élevage, environnement). Elle représente une menace croissante pour la santé publique et aucun pays n’est épargné. Il est particulièrement alarmant de constater la propagation rapide, dans le monde entier, des bactéries multirésistantes provoquant des infections courantes qui ne sont pas sensibles aux traitements antibiotiques habituellement utilisés, ainsi que des infections en particulier hospitalières, résistantes aux traitements antibiotiques de dernier recours . Le problème se pose actuellement en termes de développement durable : il dépasse largement le cadre de la santé humaine et interpelle le monde entier
AMR CONTROL – ÉDITION FRANÇAISE VOL.1
more
La RAM se produce cuando los microorganismos (bacterias, hongos, virus y parásitos) sufren cambios al verse expuestos a los antimicrobianos (antibióticos, antifúngicos, antivíricos, antipalúdicos o antihelmínticos, por ejemplo). Los microorgan...ismos resistentes a la mayoría de los antimicrobianos se conocen como ultrarresistentes.
Como resultado, los medicamentos se vuelven ineficaces y las infecciones persisten en el organismo, lo que incrementa el riesgo de propagación a otras personas.
more
A new respiratory infectious disease, COVID-19, caused by a new coronavirus called SARS-CoV-2, emerged in early December 2019. Since then, the virus has spread to India and 106 other countries in Asia, Europe, North America, Africa, and Oceania. On... March 11, the World Health Organization (WHO) declared the outbreak a pandemic, which has since rapidly evolved. As an economic hub with substantial global connectivity and movement of people and goods, India is directly impacted by the COVID-19 pandemic. Although it is too early to gauge the full spectrum of the outbreak’s social and economic impacts, COVID-19 has already caused lockdowns in China, Korea, and in many countries in Europe, and in some states of India, suspension of schools and universities, disruption of food systems and other supply chains, as well as a slowdown in trade between India and rest of the world.
more
On 31st December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. On 7th January 2020, Chinese authorities identified a new strain of Coronavirus as the causative age...nt for the disease. The virus has been renamed by WHO as SARS-CoV-2 and the disease caused by it as COVID-19. The disease since its first detection in China has now spread to over 200 countries/territories, with reports of local transmission happening in more than 160 of these countries/territories. As per WHO (as of 1st April, 2020), there has been a total of 823626 confirmed cases and 40598 deaths due to COVID-19 worldwide.
In India, as on 2nd April, 2020, 1965 confirmed cases (including 51 foreign nationals) and 50 deaths reported from 29 States/UTs. Large number of cases has been reported from Delhi, Karnataka, Kerala, Maharashtra, Rajasthan, Tamil Nadu, Telangana and Uttar Pradesh.
more
Ce cours fournit des informations sur ce que les établissements devraient faire afin d'être prêts à réagir face à un cas de virus respiratoire émergent tel que le nouveau coronavirus, sur la manière d'identifier un cas lorsqu'il se présente..., et sur la façon correcte de mettre en place des mesures de PCI pour s'assurer qu'il n'y ait pas transmission au personnel soignant ou à d'autres patients et personnes à l'intérieur de l'établissement de soins.
Cette formation s'adresse aux travailleurs de la santé et aux professionnels de la santé publique, car elle se concentre sur la prévention et la lutte contre les infections.
more
Countries who have no testing capacity and national COVID-19 laboratories with limited experience on COVID-19 virus testing are encouraged to send the first five positives and the first ten negative COVID-19 samples to WHO reference laboratories pro...viding confirmatory testing for COVID-19.
Updates 29 April 2020
more
Este documento apresenta uma orientação provisória aos laboratórios e diferentes atores envolvidos na realização de exames laboratoriais para o vírus COVID-19. Ele baseia-se parcialmente na orientação provisória para os exames laboratoriai...s do coronavírus da Síndrome Respiratória do Oriente Médio (MERS).1-6 As informações sobre a infecção em humanos pelo vírus COVID-19 estão evoluindo e a OMS continua a monitorar os acontecimentos e revisar as recomendações conforme necessário. Este documento será revisado conforme novas informações forem disponibilizadas.
more
We as a large world community are facing an extraordinary challenge: keeping healthy against the threat of rapidly spreading novel Covid-19 virus. Starting with flu-like symptoms, the virus attacks ...the airways leading to severe breathing difficulties in the m ost vulnerable, that is, those whose im m unity is decreased because of various reasons: age over 65, living with chronic illness, taking im m unity reducing medicines. Rapid spread of the virus along with severity of its sym ptom s led health specialists to recommend social distancing, confinement and thorough hand washing to our governm ents who took actions to implement these guidelines.
more
Le présent document est une mise à jour du document d’information scientifique publié le 29 mars 2020 intitulé Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precauti...on recommendations et comprend les nouvelles données scientifiques disponibles sur la transmission du SARS-COV-2, le virus responsable de la COVID-19.
more
Симптомы коронавирусной инфекции (COVID-19)
Изучите симптомы COVID-19, они могут быть такими.
corona virus symptoms
Recommendations to Member States to improve hand hygiene practices to help prevent the transmission of the COVID-19 virus: interim guidance.
WHO recommends member states provide universal access to public hand hygiene stations and making their us...e obligatory on entering and leaving any public or private commercial building and any public transport facility. It is also recommended that healthcare facilities improve access to and practice of hand hygiene.
more
Issue Brief no.8. January 18,2021
Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. B...elow is some information on vaccination strategies, implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages.
more
Ce rapport attire l’attention des intervenants sur le fait que la langue est importante pour établir la confiance avec les personnes touchées par le virus Ebola et d’autres épidémies et pour une communication efficace avec ces dernières.
27 May 2021
COVID-19 vaccines teach our immune systems how to recognize and fight the virus that causes COVID-19. Sometimes this process can cause symptoms, such as fever. These symptoms are normal and are signs that the body is building protectio...n against the virus that causes COVID-19
more
To guide One Health capacity building efforts in the Republic of Guinea in the wake of the 2014–2016 Ebola virus disease (EVD) outbreak, we sought to identify and assess the existing systems and structures for zoonotic disease detection and contro...l. We partnered with the government ministries responsible for human, animal, and environmental health to identify a list of zoonotic diseases – rabies, anthrax, brucellosis, viral hemorrhagic fevers, trypanosomiasis and highly pathogenic avian influenza – as the country's top priorities. We used each priority disease as a case study to identify existing processes for prevention, surveillance, diagnosis, laboratory confirmation, reporting and response across the three ministries. Results were used to produce disease-specific systems “maps” emphasizing linkages across the systems, as well as opportunities for improvement. We identified brucellosis as a particularly neglected condition. Past efforts to build avian influenza capabilities, which had degraded substantially in less than a decade, highlighted the challenge of sustainability. We observed a keen interest across sectors to reinvigorate national rabies control, and given the regional and global support for One Health approaches to rabies elimination, rabies could serve as an ideal disease to test incipient One Health coordination mechanisms and procedures. Overall, we identified five major categories of gaps and challenges: (1) Coordination; (2) Training; (3) Infrastructure; (4) Public Awareness; and (5) Research. We developed and prioritized recommendations to address the gaps, estimated the level of resource investment needed, and estimated a timeline for implementation. These prioritized recommendations can be used by the Government of Guinea to plan strategically for future One Health efforts, ideally under the auspices of the national One Health Platform. This work demonstrates an effective methodology for mapping systems and structures for zoonotic diseases, and the benefit of conducting a baseline review of systemic capabilities prior to embarking on capacity building efforts.
more
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna);
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– ...mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
– векторною вакциною – (Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson)
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpf...ungen)
– mit Vektor-Impfstoff – (COVID-19 Vaccine Janssen® von Janssen Cilag International/Johnson & Johnson)
more
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
...(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
(Первинна та бустерна вакцинації) – з векторною вакциною – (вакцина Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson
Станом на: 14 лютого 2022 р. (даний інформаційн...й лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)
(Grundimmunisierung und Auffrischimpfungen) – mit Vektor-Impfstoff – (COVID-19 Vaccine Janssen® von Janssen Cilag International/Johnson & Johnson)
Stand: 14. Februar 2022 (dieses Aufklärungsmerkblatt wird laufend aktualisiert)
more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Cor...ona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more